NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02149524,A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer,https://clinicaltrials.gov/study/NCT02149524,,COMPLETED,"A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting",YES,HER2 Positive Early or Locally Advanced Breast Cancer,DRUG: Herceptin (trastuzuamb)|DRUG: SB3 (proposed trastuzumab biosimilar),"The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour, Week 24","Total Pathological Complete Response (tpCR) Rate, Week 24|Overall Clinical Response Rate (ORR), Week 24|Event-free Survival (EFS), 1 month after last dose of investigational product|Overall Survival (OS), 1 month after the last administration of investigational product",,"Samsung Bioepis Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,875,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",SB3-G31-BC|2013-004172-35,2014-04,2016-03,2017-02,2014-05-29,2018-10-24,2018-10-24,"Investigational Site, Praha, Czechia",
